Compugen Stock

Compugen SGA/Revenue

The SGA to Revenue Ratio of Compugen (CGEN) as of Aug 20, 2026 is 12.22 %. In the previous year, SGA to Revenue Ratio was 33.88 % — a change of -63.93% (lower).

SGA/Revenue

12.22 %

YoY

-63.93%

Last updated:

SGA to Revenue Ratio of Compugen is 2026 12.22 % . SGA to Revenue Ratio of Compugen was 2025 33.88 % . It decreases by -63.93% lower compared to the previous year.
Access this data via the Eulerpool API

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compugen stock

SGA to Revenue Ratio of Compugen is 12.22 % in 2026.

SGA to Revenue Ratio of Compugen changed from 33.88 % to 12.22 %, representing a -63.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Compugen since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Compugen with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

Margins — Compugen

All Key Metrics — Compugen